Pharmacologic therapy of mycotic keratitis |
| |
Authors: | Pranita Sahay Deepali Singhal Ritu Nagpal Prafulla K. Maharana Marjan Farid Rachel Gelman Rajesh Sinha Tushar Agarwal Jeewan S. Titiyal Namrata Sharma |
| |
Affiliation: | 1. Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India;2. Gavin Herbert Eye Institute, University of California, Irvine, California, USA |
| |
Abstract: | Mycotic keratitis continues to be an important cause of corneal blindness, especially in tropical and subtropical countries. The prognosis is poor compared with many other forms of keratitis because of the lack of effective antifungal drugs. The currently available antifungal drugs suffer from multiple drawbacks such as poor ocular penetration, unpredictable bioavailability, and adverse effects associated with systemic medications. Over the last decade, several new drugs and drug-delivery systems have been introduced in an attempt to improve the treatment outcomes. Thorough knowledge of the currently available antifungal drugs, their spectrum of action, and associated adverse effects is essential to deal with cases of mycotic keratitis. We discuss the pharmacologic properties and clinical use of the currently available antifungal drugs. |
| |
Keywords: | Corresponding author: Prafulla K. Maharana, Assistant Professor, Department of Ophthalmology, Room- 491, 4th floor, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi-110029, India. mycotic keratitis fungal keratitis antifungal drugs natamycin voriconazole amphotericin B nanoparticle intrastromal antifungal intracameral antifungal |
本文献已被 ScienceDirect 等数据库收录! |
|